leisure time -WSS

leisure time

author：fashion 2025-09-29 01:07:28 - browse：7182

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Childhood vaccination ad campaign launches in the U.K.

WSS

It's time to retire 'poor historian' from clinicians' vocabularies

CDC panel: People 65 and older should get a Covid spring booster shot

When prostate cancer spreads, where it goes matters

Neuroscience renaissance leads to new crop of psychiatric drugs

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Ohio train derailment: Experts on toxic chemical risks

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Wearables generate powerful data but its not useful to doctors, yet

Apple is now the first public company to be valued at $3 trillion

Data integrity in scientific journals requires "effort" by publishers, institutions

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

At least 13 dead in Texas as scorching temps continue

Cytokinetics CEO stresses company can launch heart drug on its own

Virginia high school admissions case could be legal follow

NEJM study measures Covid brain fog, impact on IQ

hotspot

5 ways to address the shortage of health care workers

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

CDC advisory group OKs chikungunya vaccine

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Criminal prosecution for violating HIPAA: an emerging threat

5 ways to address the shortage of health care workers

focus

knowledge

focus

focus